Drug Trial Radar · NCT03466411
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,409
Actual
Start
Apr 13, 2018
Primary completion
Oct 20, 2023
Study completion Jan 28, 2028
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Mar 15, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease.
Conditions
- Crohn's Disease
Interventions
Guselkumab Dose 1Drug
Guselkumab will be administered by IV infusion.
Guselkumab Dose 2Drug
Guselkumab will be administered by SC injection.
Guselkumab Dose 3Drug
Guselkumab will be administered by IV infusion.
Guselkumab Dose 4Drug
Guselkumab will be administered by IV infusion.
Guselkumab Dose 5Drug
Guselkumab will be by SC injection.
GuselkumabDrug
Guselkumab will be administered by IV infusion and SC injection.
UstekinumabDrug
Ustekinumab will be administered by IV infusion and SC injection.
PlaceboDrug
Placebo will be administered as IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- GALAXI 1: Change From Baseline in the Crohn's Disease Activity Index (CDAI) Score at Week 12Time frame: Baseline and Week 12
- Global: GALAXI 2: Percentage of Participants With Both Clinical Response at Week 12 and Clinical Remission at Week 48Time frame: Weeks 48
- Global: GALAXI 2: Percentage of Participants With Both Clinical Response (CR) at Week 12 and Endoscopic Response (ER) at Week 48Time frame: Weeks 48
- Global: GALAXI 3: Percentage of Participants With Both Clinical Response at Week 12 and Clinical Remission at Week 48Time frame: Weeks 48
- Global: GALAXI 3: Percentage of Participants With Both Clinical Response (CR) at Week 12 and Endoscopic Response (ER) at Week 48Time frame: Weeks 48
- Regional: GALAXI 2: Percentage of Participants With Clinical Remission at Week 12Time frame: Week 12
- Regional: GALAXI 2: Percentage of Participants With Endoscopic Response at Week 12Time frame: Week 12
- Regional: GALAXI 3: Percentage of Participants With Clinical Remission at Week 12Time frame: Week 12
- Regional: GALAXI 3: Percentage of Participants With Endoscopic Response at Week 12Time frame: Week 12
Locations
579 sites in 43 countries. Site status is shown where the registry gives one.
Digestive Health Specialists of the Southeast
Dothan, Alabama
Internal Medicine Center
Mobile, Alabama
University of Arizona
Tucson, Arizona
Advanced Research Center Inc
Anaheim, California
Paul Wallace MD
Beverly Hills, California
University Of California San Diego
La Jolla, California
Om Research LLC
Lancaster, California
Allameh Medical Corp
Mission Viejo, California
United Gastroenterologists
Murrieta, California
Clinnova Research
Orange, California
Inland Empire Liver Foundation
Rialto, California
UC Davis Medical Center
Sacramento, California
Clinical Applications Laboratories, Inc
San Diego, California
Peak Gastroenterology Associates
Colorado Springs, Colorado
Pioneer Research Solutions Inc.
Coconut Creek, Florida
InvesClinic, LLC
Fort Lauderdale, Florida
Harmony Medical Research Institute, Inc.
Hialeah, Florida
Elite Research Network - Nature Coast Clinical Research, LLC
Inverness, Florida
SIH Research
Kissimmee, Florida
Auzmer Research
Lakeland, Florida
Florida Research Center Inc.
Lakewood Rch, Florida
Homestead Associates in Research Inc
Miami, Florida
Community Research Foundation, Inc.
Miami, Florida
Sanchez Clinical Research, Inc
Miami, Florida
Visionary Investigators Network
Miami, Florida
Gastroenterology Group Of Naples
Naples, Florida
Florida Hospital
Orlando, Florida
Omega Research Consultants
Orlando, Florida
Care Access Research, Orlando
Orlando, Florida
Synexus Clinical Research US Inc 1
Pinellas Park, Florida
Central Florida Internists
Saint Cloud, Florida
Synergy Clinical Research
St. Petersburg, Florida
Theia Clincial Research, LLC
St. Petersburg, Florida
Clinical Research of West Florida
Tampa, Florida
GCP Clinical Research
Tampa, Florida
Florida Hospital Tampa
Tampa, Florida
Alliance Clinical Research
Tampa, Florida
Cleveland Clinic Florida
Weston, Florida
Atlanta Gastroenterology Associates
Atlanta, Georgia
Morehouse School of Medicine
Atlanta, Georgia
Showing 40 of 579 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.